The US drug regulator conducted a pre-approval inspection of Piramal Pharma’s PPDS Ahmedabad facility for three days, from July 10, 2024, to July 12, 2024. The United States Food and Drug Administration (USFDA) inspection was completed with zero Form 483 observations and no action-indicated designation. Tanya Sanish, Company Secretary, informed the exchange that the successful …


